Gordon L. Snider, MD
The current acceleration of technologic advances in medicine presents physicians and society with repeated challenges. For physicians, the challenge is how best to apply the new technology; for society, the challenge is how to pay for it. The release in December 1987 of a purified preparation of human alpha-1-antitrypsin (AAT) for augmentation therapy of AAT-deficient persons typifies these problems.
The serum protein AAT, also known as alpha-1-protease inhibitor, is an inhibitor of serine proteases. Its main substrate in vivo is the serine protease, neutrophil elastase. Severe AAT deficiency is associated with the development of pulmonary emphysema in early or mid-life.
Snider GL. Pulmonary Disease in Alpha-1-Antitrypsin Deficiency. Ann Intern Med. 1989;111:957–959. doi: 10.7326/0003-4819-111-12-957
Download citation file:
Published: Ann Intern Med. 1989;111(12):957-959.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use